HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Mood disorder — Clinical Guidelines

Overview

Mood disorders encompass depressive and bipolar disorders, which are more prevalent among women and significantly impact functioning across various life stages.

Diagnosis

Clinical Assessment: Comprehensive psychiatric evaluation including symptomatology, duration, and severity 1.

Screening Tools: Utilize standardized questionnaires such as PHQ-9 for depression 1.

Laboratory Tests: Routine blood tests to rule out medical conditions mimicking mood disorders 1.

Psychological Testing: Cognitive assessments to evaluate cognitive impairment 6.

Management

First-Line Pharmacotherapy:

- Antidepressants: Selective serotonin reuptake inhibitors (SSRIs) such as sertraline or escitalopram 1. - Mood Stabilizers: For bipolar disorder, lithium or valproate 1 20.

Psychotherapy:

- Cognitive Behavioral Therapy (CBT): Effective adjunctive treatment 11. - Group Therapy: Demonstrates efficacy as an adjunct 11.

Adjunctive Treatments:

- Cognitive Remediation: Shows promise in improving cognitive functioning 7. - Sleep Interventions: Addressing insomnia may improve outcomes 9.

Special Populations

Pregnancy:

- Psychotropic Use: Follow expert guidelines from French societies for prescribing psychotropics pre, during, and post-pregnancy 3. - Monitoring: Close monitoring of both maternal and fetal outcomes 3.

Pediatrics:

- ADHD Co-morbidity: High prevalence; consider dual diagnosis approach 10. - Polypharmacy: Caution with multiple psychotropic prescriptions 19.

Elderly:

- Treatment Strategies: Tailored to account for age-related changes and comorbidities 23. - Side Effects: Heightened awareness of potential side effects and drug interactions 23.

Comorbidities:

- Medical Conditions: Integrate management of medical comorbidities to optimize mood disorder treatment 20 21.

Key Recommendations

Comprehensive Assessment: Include both clinical and psychological assessments for accurate diagnosis 1 6. (Evidence: Strong)

Integrated Treatment Approach: Combine pharmacotherapy with psychotherapy, particularly CBT, for optimal outcomes 1 11. (Evidence: Strong)

Specialized Care in Pregnancy: Follow expert guidelines for psychotropic use during pregnancy to balance maternal mental health and fetal safety 3. (Evidence: Moderate)

Monitor Cognitive Function: Incorporate cognitive assessments and remediation strategies to address cognitive impairment 6 7. (Evidence: Moderate)

Address Comorbidities: Tailor treatment plans considering coexisting medical conditions to improve overall management 20 21. (Evidence: Moderate)

References

1 Gritti LA, Reed EJ, Rayburn WF. Depression and Other Mood Disorders Across the Lifespan: Roles of the Obstetrician-Gynecologist. Obstetrics and gynecology clinics of North America 2025. link 2 Lennon C, Toscano M. Analysis of Mood and Anxiety Disorder Content in Common U.S. Obstetrics and Gynecology Residency Educational Resources. Academic medicine : journal of the Association of American Medical Colleges 2025. link 3 Belzeaux R, Gressier F, Boudieu L, Arnould A, Moreau E, Pastol J et al.. French Society for Biological Psychiatry and Neuropsychopharmacology and French-speaking Marcé Society guidelines for the management of mood disorders in women before, during, and after pregnancy. Archives of women's mental health 2024. link 4 Obikane E, Yamana H, Ono S, Yasunaga H, Kawakami N. "Association between perinatal mood disorders of parents and child health outcomes". Archives of women's mental health 2024. link 5 Kwan ATH, Rosenblat JD, Mansur RB, Rhee TG, Teopiz K, Le GH et al.. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists. Journal of affective disorders 2024. link 6 Barczyk ZA, Foulds JA, Porter RJ, Douglas KM. Childhood trauma and cognitive functioning in mood disorders: A systematic review. Bipolar disorders 2023. link 7 Goldberg Z, Kuslak B, Kurtz MM. A meta-analytic investigation of cognitive remediation for mood disorders: Efficacy and the role of study quality, sample and treatment factors. Journal of affective disorders 2023. link 8 Yamazaki R, Ohbe H, Matsuda Y, Kito S, Shigeta M, Morita K et al.. Effectiveness of medical fee revisions for psychotropic polypharmacy in patients with mood disorders in Japan: An interrupted time-series analysis using a nationwide inpatient database. Asian journal of psychiatry 2023. link 9 Palagini L, Geoffroy PA, Riemann D. Sleep Markers in Psychiatry: Do Insomnia and Disturbed Sleep Play as Markers of Disrupted Neuroplasticity in Mood Disorders? A Proposed Model. Current medicinal chemistry 2022. link 10 Sandstrom A, Perroud N, Alda M, Uher R, Pavlova B. Prevalence of attention-deficit/hyperactivity disorder in people with mood disorders: A systematic review and meta-analysis. Acta psychiatrica Scandinavica 2021. link 11 Janis RA, Burlingame GM, Svien H, Jensen J, Lundgreen R. Group therapy for mood disorders: A meta-analysis. Psychotherapy research : journal of the Society for Psychotherapy Research 2021. link 12 Le Marois M, Tzavara E, Ibrahim EC, Blin O, Belzeaux R. RNA therapeutics for mood disorders: current evidence toward clinical trials. Expert opinion on investigational drugs 2021. link 13 Dow ML, Bove E, Morgan HK, Woodland MB, Winkel AF. Resident Responses to a Wellness Survey and Significant Unreported Distress. Obstetrics and gynecology 2020. link 14 Andronis C, Silva JP, Lekka E, Virvilis V, Carmo H, Bampali K et al.. Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis. Archives of toxicology 2020. link 15 Huang CY, Yang SY, Mojtabai R, Lin SK, He YL, Chong MY et al.. Trends of Polypharmacy and Prescription Patterns of Antidepressants in Asia. Journal of clinical psychopharmacology 2018. link 16 Rapaport MH. Lori L. Altshuler, MD 1957-2015. The Journal of clinical psychiatry 2016. link 17 Rosenthal JL, Hilton JF, Teufel RJ, Romano PS, Kaiser SV, Okumura MJ. Profiling Interfacility Transfers for Hospitalized Pediatric Patients. Hospital pediatrics 2016. link 18 Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K et al.. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. The Australian and New Zealand journal of psychiatry 2015. link 19 Díaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C. Polypharmacy with antidepressants in children and adolescents. The international journal of neuropsychopharmacology 2014. link 20 Ramasubbu R, Beaulieu S, Taylor VH, Schaffer A, McIntyre RS. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2012. link 21 Ramasubbu R, Taylor VH, Samaan Z, Sockalingham S, Li M, Patten S et al.. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 2012. link 22 Tsutsumi A, Maruyama T, Nagata M. Psychiatric knowledge and skills required of occupational physicians: priorities in the Japanese setting. Journal of occupational health 2011. link 23 Rosenberg O, Shoenfeld N, Kotler M, Dannon PN. Mood disorders in elderly population: neurostimulative treatment possibilities. Recent patents on CNS drug discovery 2009. link 24 Bhat RS. You are what you eat: of fish, fat and folate in late-life psychiatric disorders. Current opinion in psychiatry 2009. link 25 . Focus on emotion and disorders of emotion. Nature neuroscience 2007. link 26 Kaplan BJ, Crawford SG, Field CJ, Simpson JS. Vitamins, minerals, and mood. Psychological bulletin 2007. link 27 Burge M, Lester D. Manic-depressiveness and Jungian dimensions of personality. Psychological reports 2000. link 28 D'Alessandro M, Lester D. Self-destructiveness and manic-depressive tendencies. Psychological reports 2000. link 29 Burge M, Lester D. Depressive and manic tendencies in high school and college students. Psychological reports 1999. link 30 Lester D. Comment on "manic-depressiveness and its correlates". Psychological reports 1999. link 31 Berrettini W. Diagnostic and genetic issues of depression and bipolar illness. Pharmacotherapy 1995. link 32 Pope HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Archives of general psychiatry 1994. link 33 Reiter SR. Mood disorders: diagnosis and treatment in the 1990s. New Jersey medicine : the journal of the Medical Society of New Jersey 1993. link 34 Livingston M. Treatment of acute major mood disturbance. The Practitioner 1989. link 35 Owens H, Maxmen JS. Mood and affect: a semantic confusion. The American journal of psychiatry 1979. link

Mood disorder